Chloroquine for Glioblastoma.

Egyptian Medical Syndicate

Status and phase: Unknown; Phase 2; Phase 1

Conditions: Glioblastoma

Treatments: Drug: Oral tablet; Drug: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT04772846

CQGBM

Details and patient eligibility

About

Adjuvant chloroquine to the conventional treatment for glioblastoma; A randomized, single-blind, placebo-controlled, phase I/II trial.

Enrollment: 60 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Histologically confirmed glioblastoma Adequate hematologic, hepatic, and renal function Karnofsky performance status score ≥ 70% Life expectancy ≥ six weeks

Exclusion criteria

Abnormal severe un-controlled medical conditions

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

60 participants in 2 patient groups, including a placebo group

Chloroquine group

Experimental group

Treatment:

Drug: Oral tablet

Placebo drug group

Placebo Comparator group

Treatment:

Drug: Placebo